Valuation: Precipio Inc

Market Cap 5.45Cr 4.67Cr 4.37Cr 4Cr 7.51Cr 521.56Cr 7.6Cr 52Cr 20Cr 262Cr 20Cr 20Cr 866.6Cr P/E 2024
-1.89x
P/E 2025 -102x
Enterprise Value 5.55Cr 4.76Cr 4.45Cr 4.07Cr 7.64Cr 531.15Cr 7.74Cr 53Cr 20Cr 266.82Cr 21Cr 20Cr 882.53Cr EV / Sales 2024
0.44x
EV / Sales 2025 1.72x
Free-Float
87.37%
Yield 2024 *
-
Yield 2025 -
Manager TitleAgeSince
Chief Operating Officer 41 -
Chief Tech/Sci/R&D Officer 42 01/06/2017
Chief Executive Officer 54 28/06/2017
Director TitleAgeSince
Director/Board Member 54 28/06/2017
Director/Board Member 78 26/09/2017
Director/Board Member 67 08/11/2017
Change 5-day change 1-year change 3-year change Capi.($)
+20.04%-15.97% - - 5.44Cr
-0.84%+3.92%+25.85%-29.38% 1.79TCr
-3.05%-7.40%-35.21%+92.83% 163.64Cr
-0.74%+3.08%-47.17%-81.88% 101.08Cr
+1.26%+0.44%-21.91%+26.08% 100Cr
+0.11%+0.11%+59.29%-6.98% 78Cr
-2.29%-1.45%-36.88%-46.39% 69Cr
-1.91%-12.67%-43.70%-46.81% 57Cr
+3.23%+2.36%-40.40%-35.27% 46Cr
+3.19%+6.69%+65.58%+47.72% 44Cr
Average +1.90%-0.82%-8.28%-8.90% 271.63Cr
Weighted average by Cap. -0.74%+2.23%+13.97%-20.00%

Financials

2024 2025
Net sales 1.85Cr 1.59Cr 1.49Cr 1.36Cr 2.55Cr 177.31Cr 2.59Cr 18Cr 6.84Cr 89Cr 6.96Cr 6.81Cr 294.61Cr 2.4Cr 2.06Cr 1.93Cr 1.76Cr 3.31Cr 230.1Cr 3.36Cr 23Cr 8.88Cr 115.59Cr 9.03Cr 8.83Cr 382.32Cr
Net income -42.9L -36.75L -34.38L -31.47L -59.07L -41Cr -59.85L -4.06Cr -1.58Cr -21Cr -1.61Cr -1.58Cr -68Cr -4L -3L -3L -3L -5L -3.47Cr -5L -34.37L -13.4L -1.74Cr -13.63L -13.33L -5.77Cr
Net Debt -1L -1L -1L -99.78T -2L -1.3Cr -2L -12.88L -5L -65.37L -5L -5L -2.16Cr 10.02L 9L 8L 7L 13.8L 9.59Cr 13.98L 94.88L 37L 4.82Cr 37.62L 36.81L 16Cr
Logo Precipio Inc
Precipio, Inc. is a healthcare biotechnology company that is focused on cancer diagnostics. The Company’s technologies include HemeScreen and IV-Cell. The HemeScreen panels test for the presence of various mutations. In developing HemeScreen, it focused on improving the economics of providing blood cancer diagnostic tests and reducing laboratory technician time consumed in the testing process. Its technology enables testing to be completed in one rapid scanning process. IV-Cell is a cell culture media that addresses the problem of diagnostic mistakes through the process of selective culturing. IV-Cell is a universal media that enables simultaneous culturing of all four hematopoietic cell lineages. Its product category includes Molecular Kits and IV-Cell Cytogenetics Media. The Molecular Kits include Quantitative MPN Panel, ABL1 Resistance Panel, and others. The Company’s laboratory and research and development (R&D) facilities are located in New Haven, Connecticut and Omaha, Nebraska.
Employees
-